The limitations of current symptom-focused treatments drive the urgent need for effective therapies for autism and Fragile X syndrome (FXS). Currently, no approved pharmacological interventions target the core symptoms of these disorders. Advances in understanding the underlying biology of autism and FXS make this an important time to explore novel options. Indeed, several treatments have recently been tested in clinical trials, with promising results in treating core symptoms of autism and FXS. We focus on emerging interventions, such as gut microbiome therapies, anti-inflammatory approaches, bumetanide, phosphodiesterase 4D inhibitors, and endocannabinoid modulators. We also discuss factors, such as disorder heterogeneity, which may have contributed to poor efficacy in previously failed late-phase trials and impact recent trials, emphasizing the need for personalized treatment approaches.

The Brain Prize 2025 went to neuro-oncologists Michelle Monje and Frank Winkler for pioneering the field of cancer neuroscience.

A team of integrative biologists at the University of Texas, Western Washington University and Columbia University Irving Medical Center has found that both wide and narrow hips provide women with certain physical benefits, though they both also have downsides. In their study published in the journal Science, the group compared hip structure among 31,000 people listed in the UK Biobank, with other physical features including those associated with pregnancy and birth.

For many years, evolutionary theorists have debated aspects of what has come to be known as the obstetrical dilemma. Prior research has shown that as humans evolved, their brains grew bigger. But prior research has also shown that as people began to walk upright, their hips grew narrower, creating a conundrum—wider hips are needed to deliver babies with bigger brains.

For this new study, the research team investigated the ways that nature has dealt with the obstetrical dilemma by studying hips and the pelvic floor.